Outsourcing

Jan 01, 2018
BioPharm International
The industry will see an impact from financing, M&As, advanced therapies, generic drugs, and the retail market in 2018.
Jan 01, 2018
BioPharm International
Recent investments show expansion activity in cell culture facilities.
Dec 19, 2017
By BioPharm International Editors
The company has completed development of a first-generation production process for its chimeric antigen receptor regulatory T cell product portfolio and is selecting a CMO for clinical supply.
Dec 14, 2017
By BioPharm International Editors
Abzena has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) to clinical trials.
Dec 13, 2017
By BioPharm International Editors
The European Medicines Agency has granted Samsung BioLogics approval to manufacture a monoclonal antibody at the company’s second facility in Songdo, Incheon, South Korea.
Dec 08, 2017
By BioPharm International Editors
The new 30,000-L, $150-million biologics manufacturing facility in Wuxi, China, quintuples the company’s existing manufacturing capability.
Dec 07, 2017
An increasing number of warning letters shows that FDA is observing more problems with pharmaceutical contract manufacturing.
Dec 06, 2017
By BioPharm International Editors
The contract research, development, and manufacturing organization has expanded API aseptic manufacturing capacity at its Valladolid, Spain, facility.
Dec 05, 2017
By BioPharm International Editors
Biopharma majors are among the industry stakeholders who have commented and raised questions about FDA’s recently proposed draft guidance for analytical assessment of similarity in biosimilars.
Dec 01, 2017
BioPharm International
The Biomanufacturing Technology Roadmap is accelerating innovative manufacturing strategies for biopharmaceuticals.
native1_300x100
lorem ipsum